Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other financing activities: 2018-2025

Historic Other financing activities for Iovance Biotherapeutics (IOVA) over the last 5 years, with Sep 2025 value amounting to -$464,000.

  • Iovance Biotherapeutics' Other financing activities rose 92.61% to -$464,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 38.41%. This contributed to the annual value of -$12.9 million for FY2024, which is 360.04% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Other financing activities of -$464,000 as of Q3 2025, which was up 7.94% from -$504,000 recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Other financing activities high stood at -$186,000 for Q4 2023, and its period low was -$6.3 million during Q3 2024.
  • Moreover, its 3-year median value for Other financing activities was -$880,000 (2024), whereas its average is -$2.0 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Other financing activities slumped by 1,556.20% in 2024 and then soared by 92.61% in 2025.
  • Iovance Biotherapeutics' Other financing activities (Quarterly) stood at -$186,000 in 2023, then plummeted by 373.12% to -$880,000 in 2024, then surged by 92.61% to -$464,000 in 2025.
  • Its Other financing activities stands at -$464,000 for Q3 2025, versus -$504,000 for Q2 2025 and -$5.6 million for Q1 2025.